Samsung Biologics to buy Swiss PolyPeptide Group in $1.8 billion
Photo illustration of a group of weight loss medications on a white background. Ucg | Universal Images Group | Getty Images South Korea’s Samsung Biologics said on Monday that it had made an all-cash bid of 1.46 billion Swiss francs ($1.8 billion) for Switzerland’s PolyPeptide Group, which specializes in peptide-based active pharmaceutical ingredients. Under the…
